Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
@violindog
Nope not a word, but that's what NDA's do.
We will not know until the evaluation is complete and a deal is struck.
Could happen any day and if it does that will be a big step forward for AvidiMab and Scancell. 🤞
The steps forward for AvidiMab :
Proof of Concept ✔️ Lab Work
In Human Trial ( Tox Safety ) ✔️ Covidity
Proof of Enhanced Avidity of an existing Mab ? ( Taking Place )
There must be NDA’s in place and Third Party lab trials happening right now.
What we are waiting for is just one of the evaluations to be successful and the first deal over the line. When that happens there will be more global interest.
Get that first one done and we are off to the races.
Regards to an offer being made, we have been told a few times that Cancer Vaccines are still on the ‘Cautious’ list of big pharma.
Our Chairman pointed out at the AGM that Big Pharma would rather pay more than get in pre-data and fall flat on their face.
All the Pre-Clinical deals we hear of are for well established drugs or very well understood Mabs.
Scancell is a pioneer and if successful will disrupt the established checkpoint dominance and eventually create new markets as they develop elements of their four platforms.
My opinion for what it’s worth is that continued positive data from the SCOPE trial, whether it’s SCIB1 or iSCIB+, will bring in a major partner or that elusive Offer for the platform.
Until our platforms produce the required level of positive data there will not be any major Interest or Offers, but there will be many suitors keeping a close watch on every Scancell announcement.
AvidiMab being used in the Covidity trial at least reassured that it was a safe addition.
It has real world benefits for many Mabs that have shown great promise but are just not potent enough on their own.
There must be some collaborations that are currently testing AvidiMabs attributes and it needs one of those to turn into a deal to spark a wider audience.
I think you also have a valid point about iSCIB+ but I would guess that Scancell will have made enough lab observations to be able to distinguish between the clinical advantages of the extra epitopes and the uplift in potency gained by adding AvidiMab.
At the last SCOPE update 13 patients had reached their scan and the data showed that 11 of those 13 had a response.
Does anyone know or could make a decent guess as to how many patients are likely to have reached the scan / data readout by the end of March ?
I know we won’t be anywhere near the 27 out of 34 goal line but could that figure be over 20 patients by then ?
Hi Violindog
There will be a milestone payment when GenMab have approval to begin a Phase1 Trial.
I know where you are coming from as Lindy did say that the larger milestones come at the backend of the deal.
I do think that there will be news concerning GenMab quite soon, where quite soon means by May or June this year.
A Haribo rocket….
‘Oh he of little faith’
If he does get a whiff of the SP increasing he will definitely give us the benefit of his wisdom. Can’t wait, it will be a sign of good things to come, like a returning comet.
Hi C11
I agree that the GenMab news has the potential to drop at anytime. Not only a milestone but LD also suggested their enquiry to take on another Mab or Target of.
We have the 6 month evaluation from last June meaning that is also a potential next news candidate. From the recent RNS's and news of conference presentations it does look as though we will see reports on both trials early in April.
Lots of potential news by the end of April, how these affect sentiment is anyone's guess but the quality of the data being shared will determine the direction.
My guess is SP in an upwards tragectory. 🤞
If Scancell seek to bring in the £40m or however much it will cost to complete a registration trial, Redmile may stay out of that raising and allow another large investor a seat at the table.
If that came to pass Redmile could convert and hold the shares at a percentage below the mandatory offer threshold.
I've not done any serious calculations rather just putting forward this idea as a possible way Redmile can keep there prominent shareholding and await a much larger deal once registration is either achieved or about to be achieved.
I think BMS are a very strong candidate to acquire Immunobody as a platform if that registration trial successfully completes.
Hi TF
The fact that the title of Lindy's presentation includes a 'MODI1 Update' does suggest that it will include data that is fuller than the brief mention in the January Interim Report.
That's how I read it anyway.
Additional to the late April Conference.
Immuno-Oncology Summit Europe 23rd & 24th April 2024.
Day 1 @ 14.45 Lindy Durrant
'Clinical Update on the DC Targeting Melanoma Vaccine, SCIB1 and Modi1 Vaccine Targeting Citrullination'
My presumption is that this will contain some new data, it doesn't say that it will but 'Clinical Update' is a perfectly good clue for me.
Chester.
Morning Maxparker
As far as I can recall there have not been any promises to update us on any trial data in the first quarter 2024.
However our CEO is presenting at a conference in late April. Please see link attached.
https://www.immuno-oncologyeurope.com/cancer-vaccines
Chester.
There is a very high probability that the Scope trial will continue in a positive way.
Just presuming for a moment that iSCIB+ plus the Doublet of CPI moves forward and successfully completes a Registration Trial.
Our ‘off the shelf’ DNA vaccine plus CPI’s will benefit the vast majority of the estimated 60,000 patients per annum.
Not only a cost effective alternative to personalised therapy’s but also very attractive to health providers like the NHS.
Immunobody will also be proven to be a highly valuable platform.
Chester.
While it feels that news is slow to arrive we must remember that SCIB1 and MODI1 are both at work in their respective patients every day.
Waiting for our next trial update is a challenge but it must be so much harder for the patients currently on our trials to await news of their treatment results.
We do know that there will be updates in April due to our conference heading at the end of that month. The next two months will fly by, Christmas is already 8 weeks in the past.
Chester.
When I considered what could be achieved this year I was thinking more along the lines of chocolate digestives and jaffa cakes piled up at this years AGM. That's what I'd call Shareholder value....... 😄
Chester.
I have followed the journey of SCIB1 from small successful trial in Resected Melanoma to the stalled FDA's clearance of Ichors ‘TriGrid’ device resulting in the change to PharmaJet needle free delivery.
You could argue that around five years were completely wasted and we could be years ahead in the current Scope trial, except for the word ‘But’ !
Three major factors have meant that SCIB1 is exactly bang on time. The FDA holding up the trial with the TriGrid device was actually a blessing as it directly lead to Scancell actively looking for an alternative.
The Pandemic allowed both the PharmaJet delivery and the in human testing of AvidiMab.
The successful rise of Checkpoint Inhibitors and especially their move to first line Standard of Care has opened up SCIB1’s chance to show off an 85% ORR.
Would Redmile have put £40m into a trial that was using Electroploration, I very much doubt it.
The SCIB1 journey has had its twists and turns but it has by this convoluted route ended up at the right time with the right delivery device backed back the right investors.
Chester.
Hi WTP
I think most of us on this board see through any such attempts to create doubt.
To be honest as we begin to receive more data from SCIB1 and Modi1 it would be interesting to see if the doomers pop up even more. A kind of ‘doom mongers’ inverse graph.
Chester.
Hi Desouzaa
The ORR of 85% achieved by Scancell when combined with the two Checkpoint Inhibitors, is amazing. There is no doubt that any other Biotech or Pharma companies in the same space will be very aware of SCIB1.
Currently the number of patients in the reported data is only small but that is being dealt with as each week passes.
If by July 2024 we have treated 35 or 40 patients and the ORR is still well above 70% ( to maintain 85% would be nice ) large Pharma will be extremely interested and the likes of Iovance will be very aware that an ‘off the shelf’ therapy has the potential to push their product to the margins.
We will see data reports by the end of Q3/24 that will have the potential to propel Scancells share price above the most recent high of 29p. The amount and quality of that data could be what I have waited for these past 10 years.
Chester.
Hiya Ray
We have probably discussed the price tag for a commercial SCIB1 + CPI treatment in the past but if it was I cannot remember the details. What would be Scancell's revenue be for a three dose treatment ?
Any rough idea would help me understand the early potential of gaining approval.
If iSCIB+ plus CPI's is successful then I could multiply by 2.5
Chester.